Limiting Skeletal Risks in Breast Cancer

Submitted by admin5 on Thu, 11/02/2017 - 16:09

According to a recent study, which therapy is most cost-effective for reducing the risk of skeletal events in breast cancer?

-----

 

A. Denosumab every month

B. Zoledronic acid every 3 months

C. Denosumab every 3 months

D. Zoledronic acid every month

-----

To see the correct answer, click here.

 

Related Content

Novel Immunotherapy Improves Survival in Advanced Breast Cancer

Prognosis Is Improving for Younger Breast Cancer Patients After Breast-Conserving Surgery